Psilocybin Mechanism of Action (MOA)

Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2024
This is an interventional, parallel arm assignment treatment study in individuals with Major Depressive Disorder (MDD). Each individual will be treated with a single dose of pimavanserin or placebo plus a single dose of psilocybin. Evaluations will be taken before dosing and following dosing at several timepoints up to 5 weeks post-dosing.
Epistemonikos ID: 7c2964d5979755992921ba9a290f489a6210f07e
First added on: Oct 01, 2024